This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Swedish Orphan Biovitrum

Drug Names(s): palifermin, rHuKGF, recombinant keratinocyte growth factor, FGF-7

Description: Keratinocyte growth factors (KGFs) are members of the fibroblast growth factor (FGF) family. Palifermin is an engineered version of FGF-7 that binds to a KGF receptor that is a splice variant of FGF receptor 2, expressed only in epithelial tissues. In preclinical studies, this protein has been shown to mediate the proliferation and differentiation of various epithelial cells such as liver cells (hepatocytes), type II lung air-sac cells (pneumocytes), specific urinary tract cells (transitional urothelial cells), specific skin cells (keratinocytes in stratified squamous epithelia), and gastrointestinal epithelial cells.

Kepivance is similar to Human Genome Sciences' Repifermin, also a recombinant KGF.

Deal Structure: Biovitrum partnered with Amgen in September 2003 to co-promote palifermin in Nordic countries.

In February 2008, Takeda agreed to acquire all of the issued and outstanding shares of Amgen K.K., Amgens subsidiary in Japan. Takeda will pay to Amgen the net asset value of Amgen K.K. as of the closing date, which shall exclude certain assets to be transferred out of Amgen K.K.

In September 2008, Biovitrum AB and Amgen announced that they entered into an agreement under which Biovitrum will acquire Kepivance and Stemgen from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret for its current approved indication.

In December 2008, Biovitrum announced the closing of an agreement, signed with Amgen in September 2008, under which Biovitrum has obtained a worldwide exclusive license to Kineret for its current approved indication, and has acquired from Amgen global rights to Kepivance and Stemgen.

After Kineret and Kepivance have reached certain...See full deal structure in Biomedtracker

Partners: Amgen, Inc.

Kepivance News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug